It is noteworthy that the development of new targeted drugs (such as TYK2 inhibitor Deucravacitinib, SMDs, etc.)and their combined therapeutic regimens have opened up new avenues for precision treatment strategies for CD. This evidence concerns the gene TYK2 and Cowden disease.